An iTRAQ Proteomics Screen Reveals the Effects of the MDM2 Binding Ligand Nutlin-3 on Cellular Proteostasis

Journal of Proteome Research

Volumn 11, Issue 11, 2012, Pages 5464-5478

  Nicholson, Judith ^a   Neelagandan, Kalainanghi ^a   Huart, Anne Sophie ^a   Ball, Kathryn ^a   Molloy, Mark P ^b   Hupp, Ted ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b MACQUARIE UNIVERSITY   (Australia)

Author keywords

interactome; iTRAQ; MDM2; NPM; Nutlin 3; protein protein interactions; proteostasis; quantitative proteomics

Indexed keywords

NUCLEOPHOSMIN; NUTLIN 3; PROTEIN MDM2; SMALL INTERFERING RNA;

AMINO ACID SEQUENCE; ANALYTIC METHOD; ANIMAL EXPERIMENT; ARTICLE; CELL STRAIN MCF 7; ITRAQ; LIGAND BINDING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOUSE; NANOANALYSIS; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN HOMEOSTASIS; PROTEIN PROTEIN INTERACTION; PROTEOMICS; UNINDEXED SEQUENCE;

BIOPOLYMERS; BLOTTING, WESTERN; CELL LINE, TUMOR; CHROMATOGRAPHY, LIQUID; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMIDAZOLES; LIGANDS; PIPERAZINES; PROTEIN BINDING; PROTEOMICS; PROTO-ONCOGENE PROTEINS C-MDM2; TANDEM MASS SPECTROMETRY;

EID: 84868306591     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr300698d     Document Type: Article

References (40)

1. Honda, R.; Tanaka, H.; Yasuda, H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53 FEBS Lett. 1997, 420 (1) 25-27
2. Deisenroth, C.; Zhang, Y. Ribosome biogenesis surveillance: probing the ribosomal protein-Mdm2-p53 pathway Oncogene 2010, 29 (30) 4253-4260
3. Wawrzynow, B.; Zylicz, A.; Wallace, M.; Hupp, T.; Zylicz, M. MDM2 chaperones the p53 tumor suppressor J. Biol. Chem. 2007, 282 (45) 32603-32612
4. Candeias, M. M.; Malbert-Colas, L.; Powell, D. J.; Daskalogianni, C.; Maslon, M. M.; Naski, N.; Bourougaa, K.; Calvo, F.; Fahraeus, R. p53 mRNA controls p53 activity by managing Mdm2 functions Nat. Cell Biol. 2008, 10 (9) 1098-1105
5. Maslon, M. M.; Hupp, T. R. Drug discovery and mutant p53 Trends Cell Biol. 2010, 20 (9) 542-555
6. Balch, W. E.; Morimoto, R. I.; Dillin, A.; Kelly, J. W. Adapting proteostasis for disease intervention Science 2008, 319 (5865) 916-919
7. Tao, W.; Levine, A. J. P19ARF stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2 Proc. Natl. Acad. Sci. U.S.A. 1999, 96 (12) 6937-6941
8. Whitesell, L.; Mimnaugh, E. G.; De Costa, B.; Myers, C. E.; Neckers, L. M. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation Proc. Natl. Acad. Sci. U.S.A. 1994, 91 (18) 8324-8328
9. Porter, J. R.; Fritz, C. C.; Depew, K. M. Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy Curr. Opin. Chem. Biol. 2010, 14 (3) 412-420
10. Vassilev, L. T.; Vu, B. T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; Kammlott, U.; Lukacs, C.; Klein, C.; Fotouhi, N.; Liu, E. A. In Vivo activation of the p53 pathway by small-molecule antagonists of MDM2 Science 2004, 303 (5659) 844-848
11. Wallace, M.; Worrall, E.; Pettersson, S.; Hupp, T. R.; Ball, K. L. Dual-site regulation of MDM2 E3-ubiquitin ligase activity Mol. Cell 2006, 23 (2) 251-263
12. Zhang, Z.; Wang, H.; Li, M.; Rayburn, E. R.; Agrawal, S.; Zhang, R. Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway Oncogene 2005, 24 (48) 7238-7247
13. Huart, A.-S.; MacLaine, N. J.; Meek, D. W.; Hupp, T. R. CK1 alpha plays a central role in mediating MDM2 control of p53 and E2F-1 protein stability J. Biol. Chem. 2009, 284 (47) 32384-32394
14. Kurki, S.; Peltonen, K.; Latonen, L.; Kiviharju, T. M.; Ojala, P. M.; Meek, D.; Laiho, M. Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation Cancer Cell 2004, 5 (5) 465-475
15. Korgaonkar, C.; Hagen, J.; Tompkins, V.; Frazier, A. A.; Allamargot, C.; Quelle, F. W.; Quelle, D. E. Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function Mol. Cell. Biol. 2005, 25 (4) 1258-1271
16. Martin, K.; Trouche, D.; Hagemeier, C.; Sorensen, T. S.; La Thangue, N. B.; Kouzarides, T. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein Nature 1995, 375 (6533) 691-694
17. Ambrosini, G.; Sambol, E. B.; Carvajal, D.; Vassilev, L. T.; Singer, S.; Schwartz, G. K. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1 Oncogene 2006, 26 (24) 3473-3481
18. Bourougaa, K.; Naski, N.; Boularan, C.; Mlynarczyk, C.; Candeias, M. M.; Marullo, S.; Fåhraeus, R. Endoplasmic reticulum stress induces G2 cell-cycle arrest via mRNA translation of the p53 isoform p53/47 Mol. Cell 2010, 38 (1) 78-88
19. Busso, C. S.; Iwakuma, T.; Izumi, T. Ubiquitination of mammalian AP endonuclease (APE1) regulated by the p53-MDM2 signaling pathway Oncogene 2009, 28 (13) 1616-1625
20. Nicholson, J.; Hupp, T. R. The molecular dynamics of MDM2 Cell Cycle 2010, 9 (10) 1878-81
21. Bischof, D.; Pulford, K.; Mason, D. Y.; Morris, S. W. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma- associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis Mol. Cell. Biol. 1997, 17 (4) 2312-2325
22. Bluemlein, K.; Gruning, N.; Feichtinger, R. G.; Lehrach, H.; Kofler, B.; Ralser, M. No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis Oncotarget 2011, 2, 393-400
23. Lee, H. H.; Kim, H. S.; Kang, J. Y.; Lee, B. I.; Ha, J. Y.; Yoon, H. J.; Lim, S. O.; Jung, G.; Suh, S. W. Crystal structure of human nucleophosmin-core reveals plasticity of the pentamer-pentamer interface Proteins: Structure, Funct., Bioinf. 2007, 69 (3) 672-678
24. Worrall, E.; Wawrzynow, B.; Worrall, L.; Walkinshaw, M.; Ball, K.; Hupp, T. Regulation of the E3 ubiquitin ligase activity of MDM2 by an N-terminal pseudo-substrate motif J. Chem. Biol. 2009, 2 (3) 113-129
25. Qi, W.; Shakalya, K.; Stejskal, A.; Goldman, A.; Beeck, S.; Cooke, L.; Mahadevan, D. NSC348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancer cells Oncogene 2008, 27 (30) 4210-4220
26. Matsuoka, S.; Ballif, B. A.; Smogorzewska, A.; McDonald, E. R.; Hurov, K. E.; Luo, J.; Bakalarski, C. E.; Zhao, Z.; Solimini, N.; Lerenthal, Y.; Shiloh, Y.; Gygi, S. P.; Elledge, S. J. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage Science 2007, 316 (5828) 1160-1166
27. van Leeuwen, I. M.; Higgins, M.; Campbell, J.; Brown, C. J.; McCarthy, A. R.; Pirrie, L.; Westwood, N. J.; Lain, S. Mechanism-specific signatures for small-molecule p53 activators Cell Cycle 2011, 10 (10) 1590-8
28. Wagstaff, K. M.; Jans, D. A. Importins and Beyond: Non-Conventional Nuclear Transport Mechanisms Traffic 2009, 10 (9) 1188-1198
29. Shoshan-Barmatz, V.; De Pinto, V.; Zweckstetter, M.; Raviv, Z.; Keinan, N.; Arbel, N. VDAC, a multi-functional mitochondrial protein regulating cell life and death Mol. Aspects Med. 2010, 31 (3) 227-285
30. Ferguson, E. C.; Rathmell, J. C. New roles for pyruvate kinase M2: working out the Warburg effect Trends Biochem. Sci. 2008, 33 (8) 359-362
31. Yang, W.; Xia, Y.; Ji, H.; Zheng, Y.; Liang, J.; Huang, W.; Gao, X.; Aldape, K.; Lu, Z. Nuclear PKM2 regulates [bgr]-catenin transactivation upon EGFR activation Nature 2011, 478 (7375) 118-122
32. Luo, W.; Hu, H.; Chang, R.; Zhong, J.; Knabel, M.; O'Meally, R.; Cole, R. N.; Pandey, A.; Semenza, G. L. Pyruvate kinase M2 Is a PHD3-stimulated coactivator for hypoxia-inducible factor 1 Cell 2011, 145 (5) 732-744
33. Ergin, M.; Denning, M. F.; Izban, K. F.; Amin, H. M.; Martinez, R. L.; Saeed, S.; Alkan, S. Inhibition of tyrosine kinase activity induces caspase-dependent apoptosis in anaplastic large cell lymphoma with NPM-ALK (p80) fusion protein Exp. Hematol. 2001, 29 (9) 1082-1090
34. Cui, Y.-X.; Kerby, A.; McDuff, F. K. E.; Ye, H.; Turner, S. D. NPM-ALK inhibits the p53 tumor suppressor pathway in an MDM2 and JNK-dependent manner Blood 2009, 113 (21) 5217-5227
35. Sundqvist, A.; Liu, G.; Mirsaliotis, A.; Xirodimas, D. P. Regulation of nucleolar signalling to p53 through NEDDylation of L11 EMBO Rep. 2009, 10 (10) 1132-1139
36. Ma, T.; Yamada, S.; Ichwan, S. J. A.; Iseki, S.; Ohtani, K.; Otsu, M.; Ikeda, M.-A. Inability of p53-reactivating compounds Nutlin-3 and RITA to overcome p53 resistance in tumor cells deficient in p53Ser46 phosphorylation Biochem. Biophys. Res. Commun. 2011, 417 (3) 931-937
37. Valentine, J.; Kumar, S.; Moumen, A. A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation BMC Cancer 2011, 11 (1) 79
38. Dastidar, S.; Lane, D.; Verma, C. Modulation of p53 binding to MDM2: computational studies reveal important roles of Tyr100 BMC Bioinform. 2009, 10 (Suppl 15) S6
39. Jin, L.; Tabe, Y.; Kojima, K.; Zhou, Y.; Pittaluga, S.; Konopleva, M.; Miida, T.; Raffeld, M. MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma Cancer Lett. 2010, 299 (2) 161-170
40. Saeed, A. I.; Bhagabati, N. K.; Braisted, J. C.; Liang, W.; Sharov, V.; Howe, E. A.; Li, J.; Thiagarajan, M.; White, J. A.; Quackenbush, J. TM4 Microarray Software Suite Methods Enzymol. 2006, 411, 134-193